JW Shinyak Corporation (067290) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of JW Shinyak Corporation KRW 1,326, price KRW 3,140, upside -57.8%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch JW Shinyak Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 1,189 KRW – 4,476 KRW · fair‑value band 892.23 KRW – 1,968 KRW · the 3,140 KRW price screens above the 1,326 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow JW Shinyak in your weekly email
Every Wednesday you see whether JW Shinyak is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
JW Shinyak Corporation, a pharmaceutical company, engages in the production and sale of medicines and medical supplies in South Korea.
Show more
JW Shinyak Corporation, a pharmaceutical company, engages in the production and sale of medicines and medical supplies in South Korea. The company offers pharmaceutical products in the areas of dermatology, urology, pediatrics, otolaryngology, etc.; and cardiovascular, gastrointestinal, urinary, NSAIDs, antibiotics, anti-fungal, anti-viral, respiratory, antihistamines, steroid hormone, anti-obesity, and other products, as well as eye drops, and antitussives and expectorants. It also develops prostate cancer treatment, liver cancer treatment, rheumatoid arthritis treatment, etc. using immune cells. The company was founded in 1981 and is based in Seoul, South Korea.
Stock analysis
JW Shinyak Corporation (067290) currently trades at 3,140 KRW, while our model-based Fair Value estimate is 1,326 KRW, implying the stock looks roughly 136.7% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 4,656 KRW per share, and 5 of the 22 models we run sit above the 3,140 KRW price.
Bear case: the Asset-Based group reads lowest at 488.32 KRW, and 17 of the 22 models stay below the price. Evidence for this calculation is medium.
Scenario range: 892.23 KRW (bear) to 1,968 KRW (bull), the price of 3,140 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
JW Shinyak Corporation reported revenue of 81.0B KRW in FY2025 versus 101B KRW in FY2021, a compound −5.3%/yr. Reported net income was 15.7B KRW in FY2025, compounding +105.2%/yr from FY2021.
Key figures
Market cap 175B KRW (≈ $129M) · P/S ratio 1.17 · Dividend yield 1.7% · Net margin 19.3% · Return on equity 4,511% · Return on assets (EBIT) −3.4% · Operating margin 5.0% · Revenue (TTM) 102B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (low confidence).
What moves the price
The share trades about 19% below its 52-week high and 150% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −41% fair-value upside, at −58%, 067290 screens richer than that median.
Fair Value models
Bear 892.23 KRWFair Value 1,326 KRWBull 1,968 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.23/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−12.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.8%
Start year 2020 (pandemic). Over 10 years: +0.5% a year
Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +28.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+27.0%
Dividend (yield on the price)1.7%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−1% → 9%
⚠ Revenue per share shrinking 1.5%/yr over ~7Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
⚠ Rate on operating basis: 2025 sits 345% above its own trend.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+29.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +27.0% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 55 stocks
Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score58 · Above median
Fair Value upside−58% · Bottom 25%
Profitability
Return on assets4% · Above median
Net margin (TTM)2% · Below median
Operating margin (TTM)5% · Below median
Growth and dividend
Revenue growth1% · Below median
Dividend yield (TTM)1.7% · Above median
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
P/FCF0.0× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 28
FUTURE (revenue growth)5· sector 63
PAST (return on equity)0· sector 10
HEALTH (low debt)100· sector 98
DIVIDEND (yield)33· sector 29
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is JW Shinyak Corporation (067290) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1,326 KRW versus a price of 3,140 KRW, about −58% upside (overvalued).
What is the fair value of 067290?
Our model-based fair value for JW Shinyak Corporation is 1,326 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 3,140 KRW.
What is the quality score of 067290?
JW Shinyak Corporation has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for JW Shinyak Corporation (067290)?
Our model-based price target is the fair value of 1,326 KRW (as of Sep 24, 2026) from 22 valuation models. Cautious scenario 892.23 KRW, optimistic scenario 1,968 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the JW Shinyak Corporation stock forecast for 2026?
Our models put fair value at 1,326 KRW, about −58% upside versus a price of 3,140 KRW (overvalued). Cautious scenario 892.23 KRW, optimistic scenario 1,968 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of JW Shinyak Corporation (067290)?
JW Shinyak Corporation reported trailing-twelve-month revenue of about 102B KRW (latest available figure, as of Sep 24, 2026).
Does JW Shinyak Corporation pay a dividend?
JW Shinyak Corporation currently shows a dividend yield of about 1.66% relative to its recent price (as of Sep 24, 2026).
What growth is priced into JW Shinyak Corporation (067290)?
For today's price to be fair in a discounted-cash-flow model, JW Shinyak Corporation would have to grow free cash flow by +29.7 % per year for five years (discount rate 12.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -4.8 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 067290 use?
Our models discount JW Shinyak Corporation at 12.7 %: a base by market capitalisation (micro), damped by beta 0.88, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For JW Shinyak Corporation that is +29.7 % per year a year over ten years, using the same discount rate (12.7 %) and the same formula as our fair value.
How much growth has JW Shinyak Corporation (067290) delivered so far?
Over the past 5 years revenue at JW Shinyak Corporation grew -4.8 % a year. The price currently implies +29.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of JW Shinyak Corporation (067290) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into JW Shinyak Corporation (+29.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of JW Shinyak Corporation (067290)?
The free-cash-flow yield on the price is 2.52 %: that much free cash flow JW Shinyak Corporation produces per unit of market value. When it exceeds the discount rate of our models (12.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of JW Shinyak Corporation (067290)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For JW Shinyak Corporation it is 1,326 KRW per share (as of Sep 24, 2026), against a price of 3,140 KRW. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is JW Shinyak Corporation stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 067290 trades above its calculated fair value: price 3,140 KRW, fair value 1,326 KRW, a gap of about −58% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 067290?
No. The price is what the market pays today (3,140 KRW); the fair value is what the company's own numbers justify (1,326 KRW). For JW Shinyak Corporation the two are 1,814 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is JW Shinyak Corporation worth?
The market values JW Shinyak Corporation at about 175B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 3,140 KRW; our models calculate a fair value of 1,326 KRW per share.
What do the bullish and bearish scenarios say about 067290?
Our models span a range for JW Shinyak Corporation: cautious scenario 892.23 KRW, base 1,326 KRW, optimistic 1,968 KRW per share (as of Sep 24, 2026, price 3,140 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 067290 from its 52-week high?
JW Shinyak Corporation trades at 3,140 KRW, about 19% below its 52-week high of 3,890 KRW and 150% above the low of 1,254 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 1,326 KRW is for.
Which stocks are comparable to JW Shinyak Corporation?
From the same area (Healthcare) we also value Caregen Co, ST Pharm Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is JW Shinyak Corporation stock attractive at the current price?
The data as of Sep 24, 2026: price 3,140 KRW, calculated fair value 1,326 KRW (−58%), Quality Score 58/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 067290 calculated?
We run JW Shinyak Corporation through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,326 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. JW Shinyak Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of JW Shinyak Corporation (067290)?
The closing price on Sep 23, 2026 was 3,140 KRW. Our model-based fair value is 1,326 KRW, about −58% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with JW Shinyak Corporation right now?
The price sits above even our optimistic bull case (1,968 KRW). The favourable scenario is already priced in. Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (892.23 KRW to 1,968 KRW) leaves room in how you read the outcome.
Key figures of JW Shinyak Corporation
How large is the market capitalisation of JW Shinyak Corporation (067290)?
The market capitalisation of JW Shinyak Corporation is 175B KRW (≈ $129M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of JW Shinyak Corporation (067290)?
The price-to-sales ratio of JW Shinyak Corporation is 1.17 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of JW Shinyak Corporation (067290)?
The dividend yield of JW Shinyak Corporation is 1.7%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of JW Shinyak Corporation (067290)?
The net margin of JW Shinyak Corporation is 19.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of JW Shinyak Corporation (067290)?
The return on equity (ROE) of JW Shinyak Corporation is 4,511% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of JW Shinyak Corporation (067290)?
On an EBIT basis the return on assets of JW Shinyak Corporation is −3.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of JW Shinyak Corporation (067290)?
The operating margin of JW Shinyak Corporation is 5.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at JW Shinyak Corporation (067290)?
Revenue at JW Shinyak Corporation is growing +1.0% versus a year earlier (3y avg −7.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at JW Shinyak Corporation (067290)?
Earnings per share at JW Shinyak Corporation are growing −64.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does JW Shinyak Corporation (067290) carry?
The net debt of JW Shinyak Corporation is 837M KRW (fiscal year 2025, ≈ 0.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch JW Shinyak Corporation in the live analysis
One click puts JW Shinyak Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
